Biomarkers.

Background: Alzheimer's Disease (AD) proteomic studies have focused on understanding the pathophysiology of AD during the late stages of AD. However, recent studies have suggested that the preclinical stage of AD represents a golden window for intervention. Yet, little is known about the influence of the cerebrospinal fluid (CSF) molecular environment on the mechanisms underlying the pathogenesis of AD during the preclinical stage.

Biomarkers.

Background: Recent Alzheimer's disease (AD) clinical trials have used CSF biomarker levels for screening and enrollment. Preliminary evidence suggests Alzheimer's Disease (AD) risk may be related to impaired renal function but the association of variation in levels of biomarkers commonly used AD biomarkers with kidney function is unknown.

Method: We conducted an analysis using data from participants enrolled in two research protocols at the Goizueta Alzheimer's Disease Research Center that had simultaneous measurements of serum creatinine at the time of their Cerebrospinal fluid (CSF) collection (N=970).

Public Health.

Background: COVID-19 has been associated with developing cognitive impairment. Individuals with cognitive impairment have a higher likelihood of progressing into dementia. Furthermore, studies have suggested that COVID-19 is associated with an increased risk of developing Alzheimer's disease (HR 2.

General Practice chest x-ray rate is associated with earlier lung cancer diagnosis and reduced all-cause mortality: a retrospective observational study.

Background: Evidence on whether general practice rates of investigation in symptomatic patients using chest x-ray (CXR) affects outcomes is equivocal.

Aim: Determine if there is an association between rates of general practice (GP) requested CXR and lung cancer outcomes.

Design And Setting: Retrospective observational study (England) Methods: Cancer registry data for patients diagnosed with lung cancer 2014-2018 was linked to data on GP CXRs 2013-2017.

Prospective evaluation of lung cancer screening eligibility criteria and lung cancer detection in the Yorkshire Lung Screening Trial.

Introduction: Low dose CT (LDCT) screening for lung cancer reduces lung cancer mortality, but there is a lack of international consensus regarding the optimal eligibility criteria for screening. The Yorkshire Lung Screening Trial (YLST) was designed to evaluate lung cancer screening (LCS) implementation and a primary objective was prospective evaluation of 3 pre-defined eligibility criteria.

Methods: Individuals who had ever smoked, aged 55-80yrs, who responded to written invitation, underwent telephone risk assessment and if eligible by at least one criteria (PLCO≥1.